JP2000504575A - 微生物のチップベースの種分化および表現型特徴付け - Google Patents
微生物のチップベースの種分化および表現型特徴付けInfo
- Publication number
- JP2000504575A JP2000504575A JP9528727A JP52872797A JP2000504575A JP 2000504575 A JP2000504575 A JP 2000504575A JP 9528727 A JP9528727 A JP 9528727A JP 52872797 A JP52872797 A JP 52872797A JP 2000504575 A JP2000504575 A JP 2000504575A
- Authority
- JP
- Japan
- Prior art keywords
- probe
- nucleic acid
- hybridization
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 244000005700 microbiome Species 0.000 title description 9
- 238000012512 characterization method Methods 0.000 title description 3
- 238000009396 hybridization Methods 0.000 claims abstract description 297
- 238000000034 method Methods 0.000 claims abstract description 210
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 154
- 241000894007 species Species 0.000 claims abstract description 150
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 46
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 46
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 21
- 239000000523 sample Substances 0.000 claims description 597
- 239000002773 nucleotide Substances 0.000 claims description 148
- 125000003729 nucleotide group Chemical group 0.000 claims description 148
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 92
- 230000000295 complement effect Effects 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 54
- 101150090202 rpoB gene Proteins 0.000 claims description 49
- 238000004458 analytical method Methods 0.000 claims description 39
- 229960001225 rifampicin Drugs 0.000 claims description 24
- 241000186359 Mycobacterium Species 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 18
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 18
- 239000002751 oligonucleotide probe Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 239000013610 patient sample Substances 0.000 claims description 17
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 13
- 239000002853 nucleic acid probe Substances 0.000 claims description 13
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 11
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 10
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 10
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 9
- 238000004590 computer program Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 101150005343 INHA gene Proteins 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 7
- 101150022921 pncA gene Proteins 0.000 claims description 7
- 101150098466 rpsL gene Proteins 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 101150070420 gyrA gene Proteins 0.000 claims description 6
- 101150013110 katG gene Proteins 0.000 claims description 6
- 229960000285 ethambutol Drugs 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 229910000498 pewter Inorganic materials 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 238000003205 genotyping method Methods 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- -1 pyratinamide Chemical compound 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 3
- 108091036078 conserved sequence Proteins 0.000 claims 3
- 229960003350 isoniazid Drugs 0.000 claims 3
- 229960000885 rifabutin Drugs 0.000 claims 3
- 206010071602 Genetic polymorphism Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 238000007621 cluster analysis Methods 0.000 claims 2
- 230000003100 immobilizing effect Effects 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 101150081550 atG gene Proteins 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 108700021469 Mycobacterium tuberculosis rpoB Proteins 0.000 abstract description 10
- 238000003556 assay Methods 0.000 abstract description 3
- 230000000875 corresponding effect Effects 0.000 description 83
- 230000035772 mutation Effects 0.000 description 40
- 201000008827 tuberculosis Diseases 0.000 description 39
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 28
- 238000003491 array Methods 0.000 description 28
- 101150085857 rpo2 gene Proteins 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 23
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 20
- 238000001514 detection method Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 230000003321 amplification Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000002966 oligonucleotide array Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000187484 Mycobacterium gordonae Species 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101150033433 Msh2 gene Proteins 0.000 description 4
- 241000186367 Mycobacterium avium Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- 238000007635 classification algorithm Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000010957 pewter Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010075028 Cytochromes b Proteins 0.000 description 2
- 108010054814 DNA Gyrase Proteins 0.000 description 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 101150110531 MLH1 gene Proteins 0.000 description 2
- 229910015837 MSH2 Inorganic materials 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000187494 Mycobacterium xenopi Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002787 antisense oligonuctleotide Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010224 classification analysis Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 102100023912 40S ribosomal protein S12 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 101100269850 Caenorhabditis elegans mask-1 gene Proteins 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 101100509674 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) katG3 gene Proteins 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000007021 Prunus avium Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 108700043532 RpoB Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241001158692 Sonoma Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 101800002712 p27 Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108010092841 ribosomal protein S12 Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005287 template synthesis Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00529—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00608—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/00626—Covalent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1133996P | 1996-02-08 | 1996-02-08 | |
| US60/011,339 | 1996-02-08 | ||
| US1263196P | 1996-03-01 | 1996-03-01 | |
| US60/012,631 | 1996-03-01 | ||
| US62903196A | 1996-04-08 | 1996-04-08 | |
| US08/629,031 | 1996-04-08 | ||
| US1776596P | 1996-05-15 | 1996-05-15 | |
| US60/017,765 | 1996-05-15 | ||
| PCT/US1997/002102 WO1997029212A1 (en) | 1996-02-08 | 1997-02-07 | Chip-based speciation and phenotypic characterization of microorganisms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000504575A true JP2000504575A (ja) | 2000-04-18 |
| JP2000504575A5 JP2000504575A5 (enExample) | 2004-11-18 |
Family
ID=27486080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9528727A Ceased JP2000504575A (ja) | 1996-02-08 | 1997-02-07 | 微生物のチップベースの種分化および表現型特徴付け |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6228575B1 (enExample) |
| EP (1) | EP0937159A4 (enExample) |
| JP (1) | JP2000504575A (enExample) |
| AU (1) | AU2189397A (enExample) |
| WO (1) | WO1997029212A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002209584A (ja) * | 2001-01-16 | 2002-07-30 | Toyobo Co Ltd | 塩基多型を検出する方法 |
| JP2005003676A (ja) * | 2003-05-19 | 2005-01-06 | Canon Inc | 情報処理装置および情報処理方法ならびに記憶媒体、プログラム |
| JP2008504844A (ja) * | 2004-07-02 | 2008-02-21 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー | リシークエンシング病原体マイクロアレイ |
Families Citing this family (251)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270961B1 (en) * | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US6919211B1 (en) | 1989-06-07 | 2005-07-19 | Affymetrix, Inc. | Polypeptide arrays |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6955915B2 (en) | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
| US20020048749A1 (en) * | 1998-04-15 | 2002-04-25 | Robert J. Lipshutz | Methods for polymorphism identifcation and profiling |
| US6741344B1 (en) * | 1994-02-10 | 2004-05-25 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US6090555A (en) * | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| US6953663B1 (en) | 1995-11-29 | 2005-10-11 | Affymetrix, Inc. | Polymorphism detection |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| US7282327B2 (en) | 1996-01-23 | 2007-10-16 | Affymetrix, Inc. | Nucleic acid labeling compounds |
| US6864059B2 (en) | 1996-01-23 | 2005-03-08 | Affymetrix, Inc. | Biotin containing C-glycoside nucleic acid labeling compounds |
| US7423143B2 (en) | 1996-01-23 | 2008-09-09 | Affymetrix. Inc. | Nucleic acid labeling compounds |
| US20010018514A1 (en) | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6965020B2 (en) | 1996-01-23 | 2005-11-15 | Affymetrix, Inc. | Nucleic acid labeling compounds |
| US7291463B2 (en) | 1996-01-23 | 2007-11-06 | Affymetrix, Inc. | Nucleic acid labeling compounds |
| US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
| FR2775984B1 (fr) | 1998-03-11 | 2006-09-15 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
| ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
| SE9602545L (sv) * | 1996-06-25 | 1997-12-26 | Michael Mecklenburg | Metod för att diskriminera komplexa biologiska prover |
| US6391550B1 (en) | 1996-09-19 | 2002-05-21 | Affymetrix, Inc. | Identification of molecular sequence signatures and methods involving the same |
| US6458584B1 (en) | 1996-12-23 | 2002-10-01 | University Of Chicago | Customized oligonucleotide microchips that convert multiple genetic information to simple patterns, are portable and reusable |
| US20020042048A1 (en) | 1997-01-16 | 2002-04-11 | Radoje Drmanac | Methods and compositions for detection or quantification of nucleic acid species |
| ATE296898T1 (de) * | 1997-03-20 | 2005-06-15 | Affymetrix Inc | Iterative resequenzierung |
| NO972006D0 (no) | 1997-04-30 | 1997-04-30 | Forskningsparken I Aas As | Ny metode for diagnose av sykdommer |
| US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| US6484183B1 (en) | 1997-07-25 | 2002-11-19 | Affymetrix, Inc. | Method and system for providing a polymorphism database |
| US6420108B2 (en) | 1998-02-09 | 2002-07-16 | Affymetrix, Inc. | Computer-aided display for comparative gene expression |
| US7068830B2 (en) | 1997-07-25 | 2006-06-27 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| JP2001514907A (ja) * | 1997-08-15 | 2001-09-18 | アフィメトリックス・インコーポレーテッド | クラスタ解析を利用した多形検出 |
| US7099777B1 (en) | 1997-09-05 | 2006-08-29 | Affymetrix, Inc. | Techniques for identifying confirming mapping and categorizing nucleic acids |
| ATE291638T1 (de) * | 1997-09-05 | 2005-04-15 | Affymetrix Inc | Techniken zur identifizierung, bestätigung, kartierung und kategorisierung von polymeren |
| US6289229B1 (en) | 1998-01-20 | 2001-09-11 | Scimed Life Systems, Inc. | Readable probe array for in vivo use |
| US6187535B1 (en) | 1998-02-18 | 2001-02-13 | Institut Pasteur | Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides |
| US7108968B2 (en) * | 1998-04-03 | 2006-09-19 | Affymetrix, Inc. | Mycobacterial rpoB sequences |
| US6324479B1 (en) * | 1998-05-08 | 2001-11-27 | Rosetta Impharmatics, Inc. | Methods of determining protein activity levels using gene expression profiles |
| ATE225859T1 (de) * | 1998-05-22 | 2002-10-15 | Creatogen Ag | Nachweis von antibiotikumresistenzen in mikroorganismen |
| US6699659B2 (en) | 1998-06-01 | 2004-03-02 | Affymetrix, Inc. | Products and methods for analyzing nucleic acids including identification of substitutions, insertions and deletions |
| CA2273616A1 (en) * | 1998-06-08 | 1999-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for parallel screening of allelic variation |
| US6185561B1 (en) | 1998-09-17 | 2001-02-06 | Affymetrix, Inc. | Method and apparatus for providing and expression data mining database |
| US6703228B1 (en) | 1998-09-25 | 2004-03-09 | Massachusetts Institute Of Technology | Methods and products related to genotyping and DNA analysis |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6489096B1 (en) | 1998-10-15 | 2002-12-03 | Princeton University | Quantitative analysis of hybridization patterns and intensities in oligonucleotide arrays |
| US6670464B1 (en) | 1998-11-17 | 2003-12-30 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| US20020150909A1 (en) * | 1999-02-09 | 2002-10-17 | Stuelpnagel John R. | Automated information processing in randomly ordered arrays |
| FR2791067B1 (fr) | 1999-03-16 | 2003-01-31 | Pasteur Institut | Sequence deletees chez m.bovis bcg/m.ou m.tuberculosis, procede de detection des mycobacteries utilisant ces sequences et vaccins |
| AU3444300A (en) * | 1999-03-24 | 2000-10-09 | Clatterbridge Cancer Research Trust | Genetic analysis |
| GB9906833D0 (en) * | 1999-03-24 | 1999-05-19 | Clatterbridge Cancer Res Trust | Genetic analysis |
| US6824866B1 (en) | 1999-04-08 | 2004-11-30 | Affymetrix, Inc. | Porous silica substrates for polymer synthesis and assays |
| US6534266B1 (en) * | 1999-04-22 | 2003-03-18 | Albert Einstein College Of Medicine Of Yeshiva University | Assay of transcription sites by multi-fluor fish |
| US20040203138A1 (en) * | 1999-04-30 | 2004-10-14 | Caren Michael P. | Polynucleotide array fabrication |
| US6821770B1 (en) | 1999-05-03 | 2004-11-23 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
| DE60038015T2 (de) * | 1999-05-03 | 2009-02-12 | Gen-Probe Inc., San Diego | Verfahren, basierend auf einer polynukleotidmatrix, zur identifizierung von mikroorganismen |
| EP1925678B1 (en) * | 1999-05-03 | 2009-07-22 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
| US20030096321A1 (en) * | 1999-05-19 | 2003-05-22 | Jose Remacle | Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips |
| DE60000583T3 (de) * | 1999-05-19 | 2009-04-30 | Eppendorf Array Technologies | Verfahren zur identifizierung und/oder quantifizierung einer zielverbindung |
| AU5870200A (en) * | 1999-06-03 | 2000-12-28 | Jonathan Hibbs | Non-cognate hybridization system (nchs) |
| US6516276B1 (en) * | 1999-06-18 | 2003-02-04 | Eos Biotechnology, Inc. | Method and apparatus for analysis of data from biomolecular arrays |
| US6713309B1 (en) | 1999-07-30 | 2004-03-30 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
| US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
| EP1076099A3 (en) * | 1999-08-03 | 2003-03-05 | Nisshinbo Industries, Inc. | Kit for diagnosis of tubercle bacilli |
| IL131324A (en) * | 1999-08-10 | 2004-01-04 | Compugen Ltd | Nucleic acid analysis method and system |
| EP1078993A1 (fr) * | 1999-08-24 | 2001-02-28 | Biomerieux | Procédé d'analyse de mesures effectuées sur une biopuce |
| US7211390B2 (en) * | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| US7244559B2 (en) | 1999-09-16 | 2007-07-17 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| WO2001029269A2 (en) | 1999-10-21 | 2001-04-26 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| EP1096024A1 (en) * | 1999-10-28 | 2001-05-02 | Remacle, José | Method and kit for the screening and/or the quantification of multiple homologous nucleic acid sequences on arrays |
| DE10000629C5 (de) * | 2000-01-10 | 2010-06-02 | november Aktiengesellschaft, Gesellschaft für Molekulare Medizin | Verfahren zur Identifizierung einer auf einen festen Körper aufgebrachten Markierung |
| US20050119473A1 (en) * | 2000-03-17 | 2005-06-02 | Affymetrix, Inc. | Phosphite ester oxidation in nucleic acid array preparation |
| EP1136566A1 (en) * | 2000-03-24 | 2001-09-26 | Facultés Universitaires Notre-Dame de la Paix | Method and kit for detection and/or quantification of homologus nucleotide sequences on arrays |
| US7202026B2 (en) * | 2000-03-24 | 2007-04-10 | Eppendorf Array Technologies Sa (Eat) | Identification of a large number of biological (micro)organisms groups at different levels by their detection on a same array |
| US7205104B2 (en) * | 2000-03-24 | 2007-04-17 | Eppendorf Array Technologies Sa (Eat) | Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays |
| US7875442B2 (en) * | 2000-03-24 | 2011-01-25 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
| US7829313B2 (en) | 2000-03-24 | 2010-11-09 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
| US20080085515A1 (en) * | 2000-03-24 | 2008-04-10 | Eppendorf Array Technologies Sa (Eat) | Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays |
| EP1285365A4 (en) * | 2000-03-28 | 2004-01-21 | Dana Farber Cancer Inst Inc | MOLECULAR DATABASE FOR ANTIBODY CHARACTERIZATION |
| TWI220927B (en) * | 2000-05-12 | 2004-09-11 | Rong-Seng Chang | Method for producing a micro-carrier |
| KR100451108B1 (ko) | 2000-05-30 | 2004-10-06 | 주식회사 바이오메드랩 | 마이코박테리아 균동정 및 약제내성 탐지를 위한 유전자진단키트 및 그 키트의 제조방법 |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| EP1164201A1 (en) * | 2000-06-14 | 2001-12-19 | Facultés Universitaires Notre-Dame de la Paix | Reverse detection for identification and/or quantification of nucleotide target sequences on biochips |
| EP1370684B1 (en) | 2000-06-15 | 2008-05-28 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides related to colon cancer |
| FR2814756B1 (fr) * | 2000-10-02 | 2004-11-19 | Univ Clermont Auvergne | Procede de detection de microorganismes |
| ATE321889T1 (de) * | 2000-07-21 | 2006-04-15 | Univ Clermont Auvergne | Verfahren zum nachweis von mikroorganismen |
| RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
| US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| AU2001290178A1 (en) | 2000-08-17 | 2002-02-25 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
| US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US20020164634A1 (en) * | 2000-08-26 | 2002-11-07 | Perlegen Sciences, Inc. | Methods for reducing complexity of nucleic acid samples |
| JP3467004B2 (ja) * | 2000-08-31 | 2003-11-17 | キヤノン株式会社 | 核酸の塩基配列の解析方法 |
| WO2002042485A2 (en) * | 2000-11-21 | 2002-05-30 | Affymetrix, Inc. | Methods and computer software products for selecting nucleic acid probes |
| AU2002227365A1 (en) | 2000-12-07 | 2002-06-18 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
| US6988040B2 (en) | 2001-01-11 | 2006-01-17 | Affymetrix, Inc. | System, method, and computer software for genotyping analysis and identification of allelic imbalance |
| WO2002072889A2 (en) * | 2001-01-12 | 2002-09-19 | Applera Corporation | Methods and compositions for microarray control |
| FR2819524B1 (fr) * | 2001-01-18 | 2003-07-04 | Antonios Vekris | Hybridation differentielle par competition |
| WO2002072779A2 (en) | 2001-03-12 | 2002-09-19 | Affymetrix, Inc. | Nucleic acid labeling compounds |
| US7052837B2 (en) * | 2001-03-13 | 2006-05-30 | The Board Of Trustees Of The University Of Arkansas | Histoplasma capsulatum catalase sequences and their use in the detection of Histoplamsa capsulatum and histoplasmosis |
| US7047141B2 (en) * | 2001-03-22 | 2006-05-16 | Ge Healthcare Bio-Sciences Ab | Ratio-based oligonucleotide probe selection |
| US20020160401A1 (en) * | 2001-03-29 | 2002-10-31 | Yasuyuki Nozaki | Biochip and method of designing probes |
| AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| JP3979793B2 (ja) * | 2001-05-29 | 2007-09-19 | 日立ソフトウエアエンジニアリング株式会社 | プローブ設計装置及びプローブ設計方法 |
| US20020187490A1 (en) * | 2001-06-07 | 2002-12-12 | Michigan State University | Microbial identification chip based on DNA-DNA hybridization |
| EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
| AU2002318944A1 (en) * | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| IL160229A0 (en) | 2001-08-10 | 2004-07-25 | Genset Sa | Polynucleotides, polypeptides encoded thereby and their use |
| US20030175740A1 (en) * | 2001-08-16 | 2003-09-18 | Mullinax Rebecca Lynn | Compositions and methods comprising control nucleic acid |
| US20030113762A1 (en) * | 2001-08-17 | 2003-06-19 | Warrington Janet A. | Gleason grade 4/5 prostate cancer genes |
| US20050123913A1 (en) * | 2001-08-30 | 2005-06-09 | Emory University | Human mitochondrial dna polymorphisms, haplogroups, associations with physiological conditions, and genotyping arrays |
| CA2356540A1 (en) * | 2001-08-30 | 2003-02-28 | Emory University | Expressed dna sequences involved in mitochondrial functions |
| US6902894B2 (en) * | 2001-09-07 | 2005-06-07 | Genetel Pharmaceuticals Ltd. | Mutation detection on RNA polmerase beta subunit gene having rifampin resistance |
| US7094542B2 (en) | 2001-09-18 | 2006-08-22 | Gen-Probe Incorporated | Detection of rpoB sequences of Mycobacterium tuberculosis |
| KR100454585B1 (ko) * | 2001-10-09 | 2004-11-02 | 주식회사 에스제이하이테크 | 마이코박테리아의 균주 감별, 결핵균의 스트레인 감별과항생제 내성을 검출하기 위한 프로브를 포함하는마이크로어레이와 이를 이용한 검출 방법 및 진단 키트 |
| CN100398551C (zh) | 2001-11-09 | 2008-07-02 | 乔治敦大学 | 新的血管内皮细胞生长抑制剂同种型 |
| US20060141493A1 (en) * | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| CA2469561A1 (en) * | 2001-12-11 | 2003-06-19 | Thomas R. Gingeras | Methods for determining transcriptional activity |
| US6897025B2 (en) * | 2002-01-07 | 2005-05-24 | Perlegen Sciences, Inc. | Genetic analysis systems and methods |
| EP1472375B1 (en) | 2002-01-08 | 2009-04-01 | Novartis Vaccines and Diagnostics, Inc. | Gene products differentially expressed in cancerous breast cells and their methods of use |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
| WO2003069333A1 (en) | 2002-02-14 | 2003-08-21 | Illumina, Inc. | Automated information processing in randomly ordered arrays |
| WO2003091391A2 (en) * | 2002-04-23 | 2003-11-06 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
| US9126165B1 (en) | 2002-04-24 | 2015-09-08 | The University Of North Carolina At Greensboro | Nucleic acid arrays to monitor water and other ecosystems |
| US8048623B1 (en) | 2002-04-24 | 2011-11-01 | The University Of North Carolina At Greensboro | Compositions, products, methods and systems to monitor water and other ecosystems |
| US8383342B2 (en) | 2002-04-24 | 2013-02-26 | The University Of North Carolina At Greensboro | Compositions, products, methods and systems to monitor water and other ecosystems |
| US7214492B1 (en) | 2002-04-24 | 2007-05-08 | The University Of North Carolina At Greensboro | Nucleic acid arrays to monitor water and other ecosystems |
| EP1900827A3 (en) | 2002-05-21 | 2008-04-16 | Bayer HealthCare AG | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
| US8518694B2 (en) | 2002-06-13 | 2013-08-27 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV |
| US20040157238A1 (en) * | 2002-09-20 | 2004-08-12 | Quinn John J. | Method for detection of multiple nucleic acid sequence variations |
| US7217519B1 (en) | 2002-11-21 | 2007-05-15 | The Board Of Trustees Of The University Of Arkansas | Histoplasma capsulatum chitin synthase sequences and their use for detection of Histoplasma capsulatum and histoplasmosis |
| EP1447454A1 (en) * | 2003-02-14 | 2004-08-18 | DR. Chip Biotechnology Incorporation | Method and apparatus for detecting pathogens |
| US20090124514A1 (en) * | 2003-02-26 | 2009-05-14 | Perlegen Sciences, Inc. | Selection probe amplification |
| US20060183132A1 (en) * | 2005-02-14 | 2006-08-17 | Perlegen Sciences, Inc. | Selection probe amplification |
| WO2004104550A2 (en) * | 2003-05-16 | 2004-12-02 | Qualicon Incorporated | Rapid and specific detection of enterobacter sakazakii |
| WO2005014857A2 (en) * | 2003-06-05 | 2005-02-17 | Wyeth | Nucleic acid arrays for detecting multiple strains of a non-viral species |
| US20050032102A1 (en) * | 2003-07-22 | 2005-02-10 | Affymetrix, Inc. | Mapping genomic rearrangements |
| US20050100911A1 (en) * | 2003-08-06 | 2005-05-12 | Perlegen Sciences, Inc. | Methods for enriching populations of nucleic acid samples |
| EP1522594A3 (en) | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| EP1670950A2 (en) | 2003-10-10 | 2006-06-21 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Method and kit for assessing anxiety or disposition thereto in a subject |
| US20050239104A1 (en) * | 2003-11-04 | 2005-10-27 | Ferea Tracy L | Microarray controls |
| GB0403039D0 (en) * | 2004-02-11 | 2004-03-17 | Health Prot Agency | TB resistance assay |
| WO2005100608A2 (en) | 2004-04-09 | 2005-10-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Diagnostic tool for diagnosing benign versus malignant thyroid lesions |
| US20070292860A1 (en) * | 2004-04-29 | 2007-12-20 | Schuren Frank H J | Staphylococcus Aureus Specific Diagnostics |
| EP1595958A1 (en) * | 2004-05-10 | 2005-11-16 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Staphylococcus aureus specific array and diagnostics |
| US7338763B2 (en) | 2004-06-02 | 2008-03-04 | Eppendorf Array Technologies S.A. | Method and kit for the detection and/or quantification of homologous nucleotide sequences on arrays |
| GB0412301D0 (en) | 2004-06-02 | 2004-07-07 | Diagenic As | Product and method |
| CA2571567A1 (en) * | 2004-06-18 | 2006-01-05 | Nimblegen Systems, Inc. | Variable length probe selection |
| US7323308B2 (en) * | 2004-09-03 | 2008-01-29 | Affymetrix, Inc. | Methods of genetic analysis of E. coli |
| FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
| US7964346B2 (en) | 2004-10-27 | 2011-06-21 | Rubin Donald H | Mammalian genes involved in infection |
| US20060166224A1 (en) * | 2005-01-24 | 2006-07-27 | Norviel Vernon A | Associations using genotypes and phenotypes |
| US20060211004A1 (en) | 2005-02-15 | 2006-09-21 | Ilsley Diane D | Methods and compositions for determining non-specific cytotoxicity of a transfection agent |
| DE102005011349A1 (de) * | 2005-03-11 | 2006-09-21 | Eppendorf Ag | Mikroarray mit Temperatur-spezifischen Kontrollen |
| JP2008537875A (ja) | 2005-03-14 | 2008-10-02 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 固形臓器移植レシピエントにおいて移植片生着を評価するための方法および組成物 |
| EP1724360A1 (en) * | 2005-05-17 | 2006-11-22 | Eppendorf Array Technologies S.A. | Identification and/or quantification method of nucleotide sequence(s) elements specific of genetically modified plants on arrays |
| US7968697B2 (en) | 2005-05-25 | 2011-06-28 | Chrontech Pharma Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
| ES2717627T3 (es) | 2005-07-29 | 2019-06-24 | Siemens Healthcare Diagnostics Inc | Métodos, kits, sistemas y bases de datos relacionados con enfermedades neoplásicas |
| DE602005005333T2 (de) | 2005-09-13 | 2008-09-18 | Eppendorf Array Technologies S.A. | Verfahren zum Nachweis von homologen Sequenzen, welche sich durch eine Base unterscheiden, auf einem Mikroarray |
| US20090264307A1 (en) * | 2006-01-13 | 2009-10-22 | The Trustees Of Princeton University | Array-based polymorphism mapping at single nucleotide resolution |
| US9445025B2 (en) | 2006-01-27 | 2016-09-13 | Affymetrix, Inc. | System, method, and product for imaging probe arrays with small feature sizes |
| US8055098B2 (en) | 2006-01-27 | 2011-11-08 | Affymetrix, Inc. | System, method, and product for imaging probe arrays with small feature sizes |
| US7951583B2 (en) * | 2006-03-10 | 2011-05-31 | Plc Diagnostics, Inc. | Optical scanning system |
| US9528939B2 (en) | 2006-03-10 | 2016-12-27 | Indx Lifecare, Inc. | Waveguide-based optical scanning systems |
| US8288157B2 (en) * | 2007-09-12 | 2012-10-16 | Plc Diagnostics, Inc. | Waveguide-based optical scanning systems |
| US9423397B2 (en) | 2006-03-10 | 2016-08-23 | Indx Lifecare, Inc. | Waveguide-based detection system with scanning light source |
| US9976192B2 (en) | 2006-03-10 | 2018-05-22 | Ldip, Llc | Waveguide-based detection system with scanning light source |
| EP2041574B1 (en) | 2006-07-14 | 2016-11-16 | The Regents of The University of California | Cancer biomarkers and methods of use threof |
| DK2099935T3 (da) * | 2006-11-30 | 2014-04-07 | Univ California | Array for detektion af mikrober |
| ES2634266T3 (es) | 2007-01-11 | 2017-09-27 | Erasmus University Medical Center | Captura de conformación cromosómica circular (4C) |
| US7838234B2 (en) | 2007-01-30 | 2010-11-23 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| US8200440B2 (en) * | 2007-05-18 | 2012-06-12 | Affymetrix, Inc. | System, method, and computer software product for genotype determination using probe array data |
| US8883691B2 (en) * | 2007-06-25 | 2014-11-11 | Affymetrix, Inc. | Encoded microparticles |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| WO2009029266A2 (en) | 2007-08-27 | 2009-03-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | Diagnostic tool for diagnosing benign versus malignant thyroid lesions |
| US8445217B2 (en) | 2007-09-20 | 2013-05-21 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
| US9146238B2 (en) | 2008-04-16 | 2015-09-29 | The Johns Hopkins University | Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
| AU2009251499B2 (en) | 2008-04-18 | 2015-07-16 | The General Hospital Corporation | Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk |
| GB2461026B (en) | 2008-06-16 | 2011-03-09 | Plc Diagnostics Inc | System and method for nucleic acids sequencing by phased synthesis |
| EP2631301B1 (en) | 2008-08-18 | 2017-10-11 | The Board of Trustees of the Leland Stanford Junior University | Methods for determining a graft tolerant phenotype in a subject |
| AU2010206843B2 (en) * | 2009-01-20 | 2015-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell gene expression for diagnosis, prognosis and identification of drug targets |
| EP3255146B1 (en) | 2009-03-16 | 2019-05-15 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
| EP2894229A1 (en) | 2009-03-27 | 2015-07-15 | Tufts Medical Center, Inc. | Markers related to age-related macular degeneration and uses therefor |
| EP2414513B1 (en) | 2009-03-31 | 2015-10-28 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
| CA2759396A1 (en) * | 2009-04-29 | 2010-11-04 | Plc Diagnostics Inc. | Waveguide-based detection system with scanning light source |
| US9290813B2 (en) | 2009-12-02 | 2016-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| EP2550371A4 (en) | 2010-03-25 | 2013-11-20 | Univ Leland Stanford Junior | PROTEIN AND GENE BIOMARKERS FOR EXTRACTING ORGAN TRANSPLANTS |
| CN103118692A (zh) | 2010-04-26 | 2013-05-22 | Atyr医药公司 | 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| WO2011139721A1 (en) | 2010-04-27 | 2011-11-10 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
| US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
| EP2563936B1 (en) | 2010-04-29 | 2018-03-14 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103118693B (zh) | 2010-04-29 | 2017-05-03 | Atyr 医药公司 | 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| ES2623805T3 (es) | 2010-05-03 | 2017-07-12 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas |
| WO2011140135A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| AU2011248355B2 (en) | 2010-05-03 | 2017-01-19 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases |
| EP2566499B1 (en) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| WO2011143482A2 (en) | 2010-05-14 | 2011-11-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| WO2011146410A2 (en) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| WO2011146725A1 (en) | 2010-05-19 | 2011-11-24 | Bayer Healthcare Llc | Biomarkers for a multikinase inhibitor |
| CA2800375C (en) | 2010-05-27 | 2021-03-09 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| WO2011153277A2 (en) | 2010-06-01 | 2011-12-08 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| WO2011156713A1 (en) | 2010-06-11 | 2011-12-15 | Vanderbilt University | Multiplexed interferometric detection system and method |
| CN103118695B (zh) | 2010-07-12 | 2016-08-03 | Atyr医药公司 | 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
| US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
| MY166040A (en) | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| WO2012102793A2 (en) | 2010-12-10 | 2012-08-02 | Zirus, Inc. | Mammalian genes involved in toxicity and infection |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| EP2673381A4 (en) | 2011-02-07 | 2014-10-15 | Univ Toronto | BIOSONDES AND METHOD FOR THEIR USE |
| US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
| US9051619B2 (en) | 2011-03-25 | 2015-06-09 | Florida Agricultural and Mechanical University (FAMU) | Methods and compositions for prostate cancer metastasis |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| HK1200329A1 (en) | 2011-04-25 | 2015-08-07 | 先进生物学实验室股份有限公司 | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| WO2012154994A2 (en) | 2011-05-10 | 2012-11-15 | The Regents Of The University Of Californa | A novel adenovirus isolated from titi monkeys |
| US10221218B2 (en) | 2011-05-10 | 2019-03-05 | The Regents Of The University Of California | Adenovirus isolated from titi monkeys |
| JP6039656B2 (ja) | 2011-06-01 | 2016-12-07 | メディカル プログノシス インスティテュート エー／エス | 癌再発の予後予測のための方法および装置 |
| DK2814514T3 (en) | 2012-02-16 | 2017-12-18 | Atyr Pharma Inc | Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases |
| US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
| NZ709167A (en) | 2012-11-27 | 2020-03-27 | Univ Pontificia Catolica Chile | Compositions and methods for diagnosing thyroid tumors |
| CN108624668B (zh) | 2013-02-01 | 2022-12-02 | 加利福尼亚大学董事会 | 用于基因组组装及单体型定相的方法 |
| US9411930B2 (en) | 2013-02-01 | 2016-08-09 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| KR101520615B1 (ko) | 2013-03-20 | 2015-05-18 | 서울대학교산학협력단 | 간암 진단용 바이오 마커 |
| JP2016518126A (ja) | 2013-04-19 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ローンスターウイルス |
| WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| EP3033088A4 (en) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| KR101527283B1 (ko) | 2013-08-13 | 2015-06-10 | 서울대학교산학협력단 | 당단백질의 탈당화 검출을 통한 암 마커 스크리닝 방법 및 간세포암 마커 |
| US10018566B2 (en) | 2014-02-28 | 2018-07-10 | Ldip, Llc | Partially encapsulated waveguide based sensing chips, systems and methods of use |
| WO2015179404A1 (en) | 2014-05-19 | 2015-11-26 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
| DK3169815T3 (da) | 2014-07-15 | 2021-02-15 | Ontario Institute For Cancer Res | Fremgangsmåder og indretninger til forudsigelse af anthracyclinbehandlingseffektivitet |
| WO2016019360A1 (en) | 2014-08-01 | 2016-02-04 | Dovetail Genomics Llc | Tagging nucleic acids for sequence assembly |
| US10435747B2 (en) * | 2014-08-19 | 2019-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Radiation biodosimetry systems |
| EP3186393A4 (en) | 2014-08-25 | 2018-01-10 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| EP3226869A4 (en) | 2014-12-03 | 2018-07-18 | Auckland UniServices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| US11543411B2 (en) | 2014-12-05 | 2023-01-03 | Prelude Corporation | DCIS recurrence and invasive breast cancer |
| JP2018506715A (ja) | 2015-01-23 | 2018-03-08 | ヴァンダービルト ユニバーシティー | 堅固なインターフェロメーター及びその使用方法 |
| JP6777966B2 (ja) | 2015-02-17 | 2020-10-28 | ダブテイル ゲノミクス エルエルシー | 核酸配列アセンブリ |
| WO2016138427A1 (en) | 2015-02-27 | 2016-09-01 | Indx Lifecare, Inc. | Waveguide-based detection system with scanning light source |
| GB2554572B (en) | 2015-03-26 | 2021-06-23 | Dovetail Genomics Llc | Physical linkage preservation in DNA storage |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| EP4019643A1 (en) | 2015-09-23 | 2022-06-29 | Oklahoma Medical Research Foundation | Biomarkers for assessing subjects with multiple sclerosis |
| JP7300831B2 (ja) | 2015-10-19 | 2023-06-30 | ダブテイル ゲノミクス エルエルシー | ゲノムアセンブリ、ハプロタイプフェージング、および標的に依存しない核酸検出のための方法 |
| US20180364243A1 (en) | 2015-12-09 | 2018-12-20 | Intuitive Biosciences, Inc. | Automated silver enhancement system |
| WO2017132483A1 (en) | 2016-01-29 | 2017-08-03 | Vanderbilt University | Free-solution response function interferometry |
| KR102744506B1 (ko) | 2016-02-23 | 2024-12-18 | 더브테일 제노믹스 엘엘씨 | 게놈 어셈블리를 위한 페이징된 판독 세트의 생성 및 반수체형 페이징 |
| US20190128895A1 (en) | 2016-04-20 | 2019-05-02 | Ldx Prognostics Limited Co. | Methods and compositions for prognosing preterm birth |
| SG11201810088SA (en) | 2016-05-13 | 2018-12-28 | Dovetail Genomics Llc | Recovering long-range linkage information from preserved samples |
| CN109196362A (zh) | 2016-05-17 | 2019-01-11 | 苏州爱尔迪思生物科技有限公司 | 用于提供子痫前期评估的方法和组合物 |
| KR102116178B1 (ko) | 2017-05-10 | 2020-05-27 | 서울대학교산학협력단 | 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도 |
| US12378592B2 (en) | 2018-01-31 | 2025-08-05 | Dovetail Genomics, Llc. | Sample prep for DNA linkage recovery |
| EP3850368A4 (en) | 2018-09-14 | 2022-11-23 | Prelude Corporation | PROCEDURE FOR SELECTING THE TREATMENT OF SUBJECTS AT RISK FOR INVASIVE BREAST CANCER |
| JP7653924B2 (ja) | 2019-06-27 | 2025-03-31 | ダブテイル ゲノミクス エルエルシー | 近接ライゲーションのための方法および組成物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| GB8810400D0 (en) * | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) * | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| AU663300B2 (en) | 1990-12-06 | 1995-10-05 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| EP0834575B1 (en) * | 1990-12-06 | 2001-11-28 | Affymetrix, Inc. (a Delaware Corporation) | Identification of nucleic acids in samples |
| IL103674A0 (en) * | 1991-11-19 | 1993-04-04 | Houston Advanced Res Center | Method and apparatus for molecule detection |
| DE4239311C2 (de) | 1992-11-23 | 1996-04-18 | Guehring Joerg Dr | Bohrer, insbesondere Spitzbohrwerkzeug mit austauschbarem Schneideinsatz |
| US5861242A (en) * | 1993-06-25 | 1999-01-19 | Affymetrix, Inc. | Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5429807A (en) * | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
| US5795716A (en) * | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5545531A (en) * | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
-
1997
- 1997-02-07 US US08/797,812 patent/US6228575B1/en not_active Expired - Lifetime
- 1997-02-07 JP JP9528727A patent/JP2000504575A/ja not_active Ceased
- 1997-02-07 AU AU21893/97A patent/AU2189397A/en not_active Abandoned
- 1997-02-07 WO PCT/US1997/002102 patent/WO1997029212A1/en not_active Ceased
- 1997-02-07 EP EP97914759A patent/EP0937159A4/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002209584A (ja) * | 2001-01-16 | 2002-07-30 | Toyobo Co Ltd | 塩基多型を検出する方法 |
| JP2005003676A (ja) * | 2003-05-19 | 2005-01-06 | Canon Inc | 情報処理装置および情報処理方法ならびに記憶媒体、プログラム |
| JP2008504844A (ja) * | 2004-07-02 | 2008-02-21 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー | リシークエンシング病原体マイクロアレイ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0937159A4 (en) | 2004-10-20 |
| WO1997029212A1 (en) | 1997-08-14 |
| US6228575B1 (en) | 2001-05-08 |
| AU2189397A (en) | 1997-08-28 |
| EP0937159A1 (en) | 1999-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000504575A (ja) | 微生物のチップベースの種分化および表現型特徴付け | |
| US7252948B2 (en) | Chip-based speciation and phenotypic characterization of microorganisms | |
| EP1124990B1 (en) | Complexity management and analysis of genomic dna | |
| US6696277B1 (en) | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes | |
| US20060199183A1 (en) | Probe biochips and methods for use thereof | |
| EP1096024A1 (en) | Method and kit for the screening and/or the quantification of multiple homologous nucleic acid sequences on arrays | |
| Wiid et al. | Oligonucleotide (GTG) 5 as a marker for Mycobacterium tuberculosis strain identification | |
| JP2003530116A (ja) | アレー上での相同ヌクレオチド配列の検出による生物学的（微）生物の同定 | |
| JP2006525814A (ja) | ヌクレオチド配列の実質的表示 | |
| WO2000039339A1 (en) | Statistical combining of cell expression profiles | |
| EP0967291A1 (en) | Method for parallel screening of allelic variation | |
| US20030049663A1 (en) | Use of reflections of DNA for genetic analysis | |
| US20040023237A1 (en) | Methods for genomic analysis | |
| Wang et al. | A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings | |
| WO1999058721A1 (en) | Multiplex dna amplification using chimeric primers | |
| EP1728875A2 (en) | Chip-based speciation and phenotypic characterization of microorganisms | |
| US20040235021A1 (en) | Authentication of biologic materials using DNA-DNA hybridization on a solid support | |
| Steinmetz et al. | High-density arrays and insights into genome function | |
| JP2002532070A (ja) | 核酸配列を解析するためのアレイおよび方法 | |
| US20090143238A1 (en) | Oligonucleotide matrix and methods of use | |
| JP2001512961A (ja) | イヌ科動物の遺伝子型決定のためのマイクロサテライト配列 | |
| Sasaki et al. | Characteristics of oligonucleotide tiling arrays measured by hybridizing full-length cDNA clones: Causes of signal variation and false positive signals | |
| US20070166714A1 (en) | Methods for preparing gene chips and use thereof | |
| HK1024937A (en) | Method for parallel screening of allelic variation | |
| Carter et al. | Array-CGH for the Analysis of Constitutional Genomic Rearrangements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060328 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060628 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060814 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20061120 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070109 |